Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00645580|
Recruitment Status : Unknown
Verified March 2008 by Sha’ar Menashe Mental Health Center.
Recruitment status was: Active, not recruiting
First Posted : March 27, 2008
Last Update Posted : February 19, 2009
|Condition or disease||Intervention/treatment|
Clinical studies have shown that adding selective serotonin reuptake inhibitor (SSRI) antidepressants to antipsychotics can improve negative symptoms of schizophrenia in patients unresponsive to antipsychotics alone (Silver and Nassar, 1992; Spina et al., 1994; Goff et al., 1995). However, the effect of SSRI augmentation on cognitive impairments of the illness has not been adequately tested.
The mechanism of SSRI augmentation is not known and is the focus of research interest.
We have recently shown that in animals, combined treatment of SSRI antidepressant and antipsychotic drug resulted in biochemical changes, different from the effects of the individual medications. Changes unique to the combined treatment were found in GABAergic components (GABA-Aβ3 receptor, glutamic acid decarboxylase 67 and PKCβ (Chertkow et al., 2005)) and changes unique to the combined treatment were found in selected areas of rat brain.
Studies of drug mechanisms in humans have utilized blood products and PMC which are readily accessible and may reflect molecular processes in the central nervous system (CNS) of schizophrenic patients (Kronfol and Remick, 2000; Avissar et al., 2001; Ilani et al., 2001; Rothermundt et al., 2001). In a recent study (Chertkow et al., 2007) which examined the gene expression profile of PMC's from antipsychotic-treated patients before the addition of the SSRI fluvoxamine, we found that mRNA expression of chemokine receptors, IL8RA and CCR1, and of RGS7 was significantly down-regulated following fluvoxamine augmentation. Additionally, the clinical assessments showed improvement in negative symptoms following the combined treatment. These findings suggested that gene expression changes in PMC's may be useful in investigating the mechanism of drug action in schizophrenia.
In this study we will examine RNA and protein expression in the course of fluvoxamine augmentation treatment. 15 chronic schizophrenic patients who have persistent negative symptoms and cognitive impairment despite adequate treatment will participate. Fluvoxamine 100mg/day will be added to the treatment regimen and continued for 6 weeks. Clinical state will be assessed using validated rating scales and cognitive performance will be assessed with a cognitive test battery. Blood samples will be taken at baseline and at 1, 3 and 6 weeks. The PMC's will be assayed using microarray, RT PCR and proteomic techniques. Changes in RNA and protein expression will be detected and compared with changes in clinical symptoms and cognitive function. Identification of biochemical changes related to augmentation treated and their relation to symptomatic and cognitive changes will be the major potential benefit of the study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function|
|Study Start Date :||April 2008|
|Estimated Primary Completion Date :||April 2009|
|Estimated Study Completion Date :||April 2009|
Fluvoxamine 100mg/day PO for 6 weeks.
- Schedule for the Assessment of Negative Symptoms (SANS) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Schedule for the Assessment of Positive Symptoms (SAPS) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Simpson Angus Scale for Extrapyramidal Side Effects (SA) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Abnormal Involuntary Movement Scales (AIMS) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Calgary Depression Scale [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Mini Mental State Examination [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Dot test (Keefe et al., 1997) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Digit Span (Wechsler, 1998) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Finger Tap Test (Reitan and Davison, 1974) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Wechsler memory tests (Wechsler, 1998) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
- Computerized Cognitive Neuropsychological Battery (Silver et al 2003) [ Time Frame: 0 weeks, 3 weeks, 6 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00645580
|Sha'ar Menashe Mental Health Center|
|Mobile Post Hefer, Israel, 37806|
|Principal Investigator:||Henry Silver, PhD||Sha'ar Menshae Mental Health Center|